Report

Trading Update

RUA have released a trading update ahead of its December interim results announcement. In contrast to the previous year, revenues have been weighted to the second half and while this has suppressed first half revenue growth, October’s and November’s revenues have largely caught up to align with management’s budget expectations.

RUA’s recent strategy update and its trading update have several common themes. The reliance on partnerships to fund the development of RUA’s products in RUA Structural Heart and RUA Vascular should reduce R&D and Admin expenditure and conserve cash to provide a pathway for the Group to reach profitability. The continued emphasis on tight resource control is expected to help with this objective.

Our valuation is unchanged at £120.3m or 542p per share.
Underlying
Rua Life Sciences

Aortech International is an Intellectual Property (IP) holding company whose principal activity is exploiting the value of its IP and know-how.

Provider
Equity Development
Equity Development

​Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.

Analysts
Andy Smith

Other Reports on these Companies
Other Reports from Equity Development

ResearchPool Subscriptions

Get the most out of your insights

Get in touch